Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous clonal disease of myeloid neoplasms characterized by ineffective hematopoiesis, variable degree of cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). Molecular and genetic characterization of MDS has led to a better understanding of the disease pathophysiology and is leading to the development of novel therapies. Targeted and immune therapies have shown promising results in different hematologic malignancies. However, their potential use in MDS is yet to be fully defined. Here, we review the most recent advances in therapeutic approaches in MDS, focusing on higher-risk disease. Allogeneic hematopoietic cell transplantation is beyond the scope of this article.
Original language | English |
---|---|
Article number | 124 |
Journal | Journal of Hematology and Oncology |
Volume | 15 |
Issue number | 1 |
DOIs | |
State | Published - Dec 2022 |
Externally published | Yes |
Keywords
- High-risk MDS
- Immune dysregulation
- Immunotherapy
- Myeloid malignancy
- Precision medicine
- Targeted therapy